We report a @entity900 and @entity2600 combination in @entity1 with biopsy-proven advanced @entity788 . @entity1 were selected from a specialist centre and required good performance status (KPS>70%), measurable disease on CT scan, and biochemical and haematological parameters within normal limits. Based on a two-stage phase II design, we aimed to treat 22 @entity1 initially. The study was stopped because of the death of the 19th @entity1 during the first treatment cycle, with @entity1398 and @entity177 . A total of 89 treatments were administered to 17 @entity1 . Serious grade 3/4 @entity137 were haematological ( @entity1398 ) 6%, @entity294 6%, @entity390 7% and vomiting 6%. Using the clinical benefit response (CBR) criteria, no @entity1 had an overall CBR. For responses confirmed by CT examination, there was one partial response (5%), three stable diseases lasting greater than 6 weeks (16%), with an overall 22% with disease control (PR+SD). The median progression-free and overall survival was 3.1 months (95% CI: 1.3-3.7) and 5.0 (95% CI: 3.9-10.1) months, respectively. Although this synergistic combination has improved the response rates and survival of other solid @entity5 , we recommend caution when using this combination in the palliation of advanced @entity788 , because of unexpected @entity137 .

A phase II @entity2600 - XXXX combination in advanced @entity788 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'pancreatic adenocarcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity177 :: ('MESH:D051437', 'Disease') :: ['multiorgan failure'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'neutropenic sepsis']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
